The Pharma Data

JULY 29, 2021

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) . United States and virtually from July 26 to 30, 2021 (Presentation No.:

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. Late Breaking Oral Presentation OALC01LB03. Abstract 2361.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Treatment 52

The Pharma Data

JANUARY 21, 2021

.–( BUSINESS WIRE )– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 21, 2020

and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. These findings were presented today at the 2020 Infectious Diseases Society of America (IDSA) IDWeek.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. AR-301 (VAP). AR-101 (HAP).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

LifeSciVC

OCTOBER 10, 2024

At the congress, we were thrilled to share some of the clinical data emerging from our Phase 1 program , an ongoing study evaluating our potent and selective investigational CBL-B inhibitor, HST-1011, in patients with advanced solid tumors. The post ESMO Reflections: Glimmers of Hope with the Next Wave of I-O Therapies?

Therapies 74

Therapies Clinical Development Pharmacokinetics Treatment 74

The Pharma Data

JANUARY 7, 2021

a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang , M.D., The Company’s presentation will be available on-demand from January 11 – 14, 2021. SAN CARLOS, Calif. , 7, 2021 /PRNewswire/ — Apexigen, Inc. , The Company will be conducting one-on-one meetings. About Apexigen.

Clinical Development 40

Clinical Development International Production Drugs 40

The Pharma Data

JULY 28, 2021

The TAK-994 BTD was based, in part, on early phase and preliminary clinical data that indicates Takeda’s investigational oral orexin agonist may demonstrate substantially improved objective and subjective measurements of daytime wakefulness in NT1 patients. 1 Currently, TAK-994 is being studied in an ongoing Phase 2 (TAK-994-1501) study.

Clinical Development 52

Clinical Development Therapies Laboratories Treatment 52

KIF1A

MARCH 16, 2024

The study identified 8 groups based on symptom presentation, and found over 70 disease-associated genes, including 4 patients with KIF1A mutations. While genetic disorders like KAND make up only a small part of this number, this represents the need for increased investment in neuroscience research and clinical development.

Disease 105

Disease Clinical Development Research Treatment 105

The Pharma Data

NOVEMBER 14, 2020

The results were presented at The Liver Meeting Digital Experience (TLMdX), November 13–16, 2020 (Late Breaker #L02). The companies are also presenting preclinical data supporting the development of combination approaches in NASH. We are now carefully evaluating next steps together based on a thorough assessment of data.”.

Trials 52

Trials Science Treatment Disease 52

The Pharma Data

SEPTEMBER 2, 2020

Other data to be presented will show high treatment persistence and strong adherence for patients treated with OCREVUS compared to other DMTs in real-world settings. A full list of Roche presentations can be found at: [link]. Presentations at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting include: Medicine. Abstract Title.

Clinical Trials 52

Clinical Trials Treatment Disease Therapies 52

The Pharma Data

NOVEMBER 4, 2020

5, 2020 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that its CD40 targeting antibody mitazalimab will be presented at the World Immunotherapy Congress, November 2-6, 2020. The presentation will also summarize previously released clinical data from the Phase I study performed by Janssen Biotech Inc.

Packaging 40

Packaging Clinical Development Disease Drugs 40

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

The Pharma Data

JANUARY 20, 2021

In addition, a video of the Company’s corporate presentation with comments by Snehal Patel will be available on the investor section of the Company’s website here. Riley Securities Oncology Investor Conference: The Company will present at the virtual B. The presentation will be live and available to conference attendees.

Clinical Trials 40

Clinical Trials Trials Clinical Development Treatment 40

Drug Target Review

FEBRUARY 1, 2024

There are a lot of drug development challenges that are, in some cases, unique to neuroscience, including neurological diseases, psychiatric disorders, and rare diseases affecting the nervous system. Part of the challenge is that patients present with very different kinds of clinical phenotypes, meaning the populations are heterogeneous.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

The Pharma Data

OCTOBER 21, 2020

(Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present a poster on SYNB8802, an investigational Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria (HOX), during the American Society of Nephrology (ASN) Kidney Week, Oct.

Clinical Trials 40

Clinical Trials Engineering Clinical Development Treatment 40

Drug Target Review

JANUARY 8, 2024

Jerry has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialisation of more than a dozen FDA-approved drugs with multiple successful exits. What’s next for Life Bioscience’s preclinical studies?

Science 145

Science Disease FDA Approval Clinical Trials 145

The Pharma Data

APRIL 11, 2023

The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models. Data from all three areas of scientific focus will be showcased during this year’s meeting.

Research 40

Research Clinical Trials Small Molecule Trials 40

The Pharma Data

OCTOBER 28, 2020

Dr. Maurice Zauderer, chief executive officer of Vaccinex, will present, “Learnings from the SIGNAL Phase 2 Study of Treatment with Pepinemab Antibody,” at 10:00 am ET on Friday, October 30. These new data suggest that pepinemab has the potential to provide cognitive benefit and slow brain atrophy in HD patients.

Clinical Trials 40

Clinical Trials Treatment Disease Clinical Development 40

The Pharma Data

JANUARY 27, 2021

ET ) to discuss the results and next steps in clinical development of BI-1206. Renowned lymphoma expert Mats Jerkeman, MD, Lund University, will give a presentation on the current treatment landscape, and unmet medical need for patients with relapsed or refractory NHL. CET ( 11:30 a.m.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

KIF1A

SEPTEMBER 30, 2023

This program will encourage therapeutic sponsors to communicate with FDA officials more regularly and as needed to improve their clinical development of gene- and cell-based therapies. What’s a pre-print? Check out this #ScienceSaturday post to learn more.

Disease 111

Disease FDA Clinical Trials Therapies 111

Fierce BioTech

MAY 29, 2024

Redefining Antibody Specificity Profiling for IND Assessment of antibody off-target reactivity is a regulatory requirement for clinical development, but conventional methods are often ineffective, and their predictive value for in vivo safety and toxicity is poor.

Clinical Development 52

Clinical Development 52

PPD

OCTOBER 17, 2024

This expansion represents a significant opportunity for both drug developers and patients, while also presenting a new and diverse set of challenges for drug developers, particularly in clinical trial execution. Factoring in cultural dynamics is key to enabling new therapy treatment success.

Therapies 97

Therapies Clinical Trials Clinical Research Trials 97

The Pharma Data

JUNE 2, 2023

Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15. & SANTA MONICA, Calif.–(BUSINESS

Therapies 52

Therapies Clinical Development Treatment Trials 52

Drug Target Review

FEBRUARY 10, 2025

Ive been involved in therapeutics development for over 25 years, working with small, medium, and large biotech companies. My focus has always been on advancing novel medicines from research to clinical development. Over the years, Ive had the privilege of working on more than 25 different products, Bock shared.

Therapies 64

Therapies Treatment Engineering Clinical Trials 64

The Pharma Data

SEPTEMBER 16, 2020

executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team and clinical investigators, will discuss Phase 1 data being presented on the Company’s investigational KRAS G12C inhibitor sotorasib (AMG 510). Reese , M.D., On Monday, Sept.

Clinical Development 52

Clinical Development Therapies Disease Research 52

Conversations in Drug Development Trends

JANUARY 24, 2024

Much of what we discuss I covered in my presentation, “Leveraging Genetics to Support Rare Disease Clinical Trials,” at last year’s World Orphan Drug Congress (WODC) EU. One diagnostic example that I discussed in my presentation is autism. Enrolling adequate populations will be required to advance these programs.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Alta Sciences

NOVEMBER 15, 2024

As the CRO, our role is to provide a broader perspective and identify additional areas where our expertise can support their development program,” explains Lisa. For example, at Altasciences, we can discuss clinical development strategies that include adding study arms such as ethnobridging , or early precision QT analysis assessments.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

Conversations in Drug Development Trends

NOVEMBER 21, 2023

As a provider of end-to-end clinical development solutions, we plan to leverage our expertise to refine drug-disease matches identified by Every Cure’s use of AI and data analysis. At Worldwide, we deliver full-service clinical development to support drug approval and commercialization.

Disease 78

Disease Treatment Clinical Trials Clinical Development 78

Conversations in Drug Development Trends

DECEMBER 20, 2023

In November 2023, at Outsourcing Clinical Trials Dach in Zurich, our Executive Director, Oncology Strategy Lead, Matt Cooper , presented “Delivering Oncology Studies – Challenges and Considerations.”

Clinical Trials 83

Clinical Trials Trials Pharmacokinetics FDA 83

Drug Target Review

DECEMBER 13, 2023

This is likely indicative of the heterogeneous nature of the disorder, and it is this complexity and diversity of clinical presentation and effects across multiple organ systems, that has made efforts to identify genetic risk factors using traditional genomic analysis approaches extremely challenging.

Bioinformatics 145

Bioinformatics Disease Regulations Immune Response 145

Drug Target Review

JUNE 6, 2023

In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour. Some approaches have already reached the clinical trial stage, with others not far behind. 2 After activation by an antigen presenting cell, a T helper cell segregates the cytokines.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Target Review

APRIL 3, 2024

Our research demonstrated that GDF-15 acts as a versatile tool for tumours to inhibit the mounting of an effective antitumoral immune response at various steps of its process, including antigen presentation, immune cell activation, and their migration and infiltration into the tumour.

Science 105

Science Clinical Development Treatment DNA 105

Drug Target Review

JULY 20, 2023

From the 73 long COVID-associated genes, 42 hold potential for novel drug discovery, with 13 already targeted by drugs in clinical development pipelines. From the 73 long COVID-associated genes, 42 hold potential for novel drug discovery, with 13 already targeted by drugs in clinical development pipelines.

Clinical Development 75

Clinical Development Regulations Disease Treatment 75

Fierce BioTech

DECEMBER 23, 2024

and often require consistent batches of drug product be administered to groups of research participants within a short timeframe, early phase studies present unique challenges for drug developers not typically experienced in later stages of development. First-in-Human, Drug-Drug Interaction, Food Effect, Bioequivalence, etc.),

Pharmacy 52

Pharmacy Trials Clinical Trials Clinical Development 52

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Treatment 52

Treatment Disease Therapies Pharmaceuticals 52

SugarCone Biotech

JUNE 10, 2024

[link] Immunity is complex and can be dangerous when exploited clinically, as demonstrated by the lethal administration of TNF, or anti-CD40L antibody (Biogen) or CAR-T cells expressing the CD16 Fc-receptor (Unum), among many other examples. This observation may be important given the critical role of DC in tumor antigen presentation.

Immune Response 88

Immune Response Production Regulations Clinical Trials 88